Back to Ovarian Cancer
NCT05292859
NCT05292859
Who may be able to join
Who might be able to join this trial:
- You must have already received a TCR-T cell treatment (a type of immune cell therapy) as part of a previous Alaunos study (such as study TCR001-201), whether you completed that study or left it early.
- You must be willing and able to attend the required study visits and follow the study's guidelines.
- You must be able to understand and sign a consent form, agreeing to the study's requirements.
- You must agree to allow blood or tissue samples to be collected and stored by the study site and/or the company running the trial (Alaunos Therapeutics) for testing purposes.
Who may not be able to join:
- If you signed up for a related Alaunos study but never actually received the TCR-T cell treatment, you would not be eligible for this trial.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Trial details
Status
Completed
Phase
Not Applicable
Sponsor
Alaunos Therapeutics
Registry
clinicaltrials_gov
Start date
1 March 2023
Est. completion
30 May 2025
Where this trial is recruiting
🇺🇸 United States
Primary endpoints
To assess the long-term safety of subjects that have received neoantigen-specific TCR-T cells; To assess the long-term safety of subjects that have received neoantigen-specific TCR-T cells
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.